Northwest & Ethical Investments L.P. Sells 1,808 Shares of Illumina, Inc. (NASDAQ:ILMN)

Northwest & Ethical Investments L.P. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 60,854 shares of the life sciences company’s stock after selling 1,808 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Illumina were worth $8,132,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new stake in Illumina during the 4th quarter valued at $751,000. Zacks Investment Management purchased a new stake in Illumina during the 3rd quarter valued at $2,924,000. Van ECK Associates Corp boosted its position in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after buying an additional 22,718 shares during the period. Strategic Financial Concepts LLC purchased a new stake in Illumina during the 4th quarter valued at $1,464,000. Finally, Allworth Financial LP boosted its position in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after buying an additional 6,263 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the subject of several research reports. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a report on Friday, February 28th. Morgan Stanley decreased their price objective on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Stephens restated an “overweight” rating and issued a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Finally, Barclays reiterated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $140.90.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $84.79 on Friday. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66. The business has a fifty day moving average price of $109.19 and a 200-day moving average price of $128.58. The company has a market capitalization of $13.43 billion, a PE ratio of -11.04, a PEG ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.